Adamas Pharmaceuticals Inc

Most Recent

  • uploads///Supernus
    Company & Industry Overviews

    A Financial Overview of Supernus Pharmaceuticals in September

    In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today

    Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4.

    By Daniel Collins
  • uploads///Fei
    Company & Industry Overviews

    Why Axovant Sciences Stock Rose in Week Ended June 8

    On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.